Skip to main content
Premium Trial:

Request an Annual Quote

Illumina TruSight Oncology 500

Illumina has launched TruSight Oncology 500 (TSO 500), a pan-cancer assay to identify known and emerging biomarkers. The assay, which is for research use only and will start shipping in the first quarter of 2019, uses both DNA and RNA from tumor samples to identify somatic variants, including small variants, gene fusions, and splice variants. It can also measure tumor mutational burden and microsatellite instability. The assay covers a large number of genes as well as 1.94 megabases of the genome to measure TMB.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.